University of Texas's MD Anderson Cancer Center: RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
September 13, 2022
September 13, 2022
HOUSTON, Texas, Sept. 13 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Targeted therapy, previously shown to be effective in lung and thyroid cancers, displays clinically meaningful activity in an expanded field of tumor types
* * *
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I . . .
* * *
Targeted therapy, previously shown to be effective in lung and thyroid cancers, displays clinically meaningful activity in an expanded field of tumor types
* * *
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I . . .